AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 10 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Immunization with heat shock protein 70 prevented development of methylcholanthrene-induced sarcomas in mice, according to researchers at Karolinska Institute in Stockholm.
Tumor and viral studies in animal models have shown that vaccines containing members of the heat shock protein 70 (hsp 70) family confer protection through binding of antigenic peptides. A.M. Ciupitu and collaborators investigated the effects of hsp 70 on methylcholanthrene-induced sarcomas MC57S and MC57X, which express different major histocompatibility complex class I (MHC-I) peptides.
"With hsp70 purified from tumor or liver tissue, we were able to confirm that tumor-derived hsp70 elicited in vivo protection against a challenge with the same tumor as that used for hsp70 isolation," reported Ciupitu and colleagues. "We also observed that immunizing with hsp70 isolated from tumor tissue resulted in a significantly better protection than immunizing with hsp70 isolated from the liver tissue of healthy mice."
However, both vaccines - liver-derived hsp 70 and tumor-derived hsp 70 - significantly slowed tumor outgrowth (compared with saline control) in two of three experiments (Immunization with heat shock ...
Source: HighBeam Research, Heat shock protein 70 protects against methylcholanthrene-induced...